Remove Laboratories Remove RNA Remove Virus
article thumbnail

Discovery and development of COVID?19 vaccine from laboratory to clinic

Chemical Biology and Drug Design

WHO proclaimed the outbreak of the Ebola virus disease (EVD), in 2014 that killed hundreds of people in West Africa. The development of vaccines for SARS-CoV-2 becomes more difficult due to the viral mutation in its non-structural proteins (NSPs) especially NSP2 and NSP3, S protein, and RNA-dependent RNA polymerase (RdRp).

Vaccine 100
article thumbnail

Simple test for flu could improve diagnosis and surveillance

Broad Institute

Simple test for flu could improve diagnosis and surveillance By Allessandra DiCorato June 18, 2024 Breadcrumb Home Simple test for flu could improve diagnosis and surveillance A low-cost CRISPR-based paper strip test distinguishes between influenza types and can be reprogrammed to recognize different viruses including the H5N1 bird flu virus.

Virus 144
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Evolved prime editors are smaller and more efficient for therapeutic applications

Broad Institute

Now researchers at the Broad Institute of MIT and Harvard have used cutting-edge continuous laboratory evolution and engineering methods to develop improved versions of the gene-editing tool. Reverse transcriptase proteins that copy RNA templates into strands of DNA are found naturally in all plant and animal cells and in many viruses.

DNA 145
article thumbnail

Phages could help to tackle antimicrobial resistance

Drug Target Review

Researchers from the Laboratory of Bacteriology at The Rockefeller University have now found that bacteria sense phages by a defensive response named CBASS (cyclic oligonucleotide-based antiphage signalling system) which detects viral RNA. The novel, hairpin-shaped molecule was named cabRNA for CBASS-activating bacteriophage RNA.

RNA 59
article thumbnail

Preliminary Findings from a Phase 2a Trial of Investigational COVID-19 Therapeutic Molnupiravir

The Pharma Data

The companies today reported findings on one secondary objective from the Phase 2a study, showing a reduction in time (days) to negativity of infectious virus isolation in nasopharyngeal swabs from participants with symptomatic SARS-CoV-2 infection, as determined by isolation in Vero cell line culture. About Molnupiravir.

Trials 69
article thumbnail

High-Content Imaging siRNA Screens Identify Trafficking Factors in Alphavirus Infection

PerkinElmer

The complex relationship between a virus and its host is one of the hottest topics in science right now, and has been given considerable attention in recent weeks as a result of the race to understand the virus that causes COVID-19 and its potential vulnerabilities.

RNA 52
article thumbnail

Spectrum Solutions Secures Emergency Use Authorization (EUA) for its SDNA-1000 Saliva Collection Device, Expanding Access and COVID-19 Testing Options

The Pharma Data

Spectrum’s self-contained saliva collection kit provides critical sample consistency while suspending and neutralizing viral RNA transcripts completely inactivating the live virus. Qualified commercial RNA extraction chemistries include Perkin Elmer, Thermo Fisher, Roche, and Qiagen. This press release features multimedia.

RNA 52